{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T03:56:26Z","timestamp":1777521386055,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100009053","name":"The Wellcome Trust DBT India Alliance","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s10792-021-02113-4","type":"journal-article","created":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T16:20:42Z","timestamp":1636474842000},"page":"1263-1272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dexamethasone implant improves anatomic response to anti-VEGF therapy in treatment-resistant polypoidal choroidal vasculopathy"],"prefix":"10.1007","volume":"42","author":[{"given":"Kushanth","family":"Mallikarjun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9688-5859","authenticated-orcid":false,"given":"Raja","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Raman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashik","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahesh P.","family":"Shanmugam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajendra S.","family":"Apte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srikant Kumar","family":"Padhy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,9]]},"reference":[{"issue":"8","key":"2113_CR1","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1097\/IAE.0b013e31824f91e8","volume":"32","author":"A Koh","year":"2012","unstructured":"Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H et al (2012) EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 32(8):1453\u20131464","journal-title":"Retina"},{"issue":"7","key":"2113_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1001\/jamaophthalmol.2018.1804","volume":"136","author":"WK Lee","year":"2018","unstructured":"Lee WK, Iida T, Ogura Y, Chen SJ, Wong TY, Mitchell P et al (2018) Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study: A Randomized Clinical Trial. JAMA Ophthalmol 136(7):786\u2013793","journal-title":"JAMA Ophthalmol"},{"key":"2113_CR3","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","volume":"119","author":"DF Martin","year":"2012","unstructured":"Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388\u20131398","journal-title":"Ophthalmology"},{"key":"2113_CR4","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD et al (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537\u20132548","journal-title":"Ophthalmology"},{"key":"2113_CR5","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1136\/bjo.2006.113902","volume":"91","author":"A Lux","year":"2007","unstructured":"Lux A, Llacer H, Heussen FM, Joussen AM (2007) Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 91:1318\u20131322","journal-title":"Br J Ophthalmol"},{"key":"2113_CR6","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1136\/bjophthalmol-2013-303513","volume":"97","author":"I Krebs","year":"2013","unstructured":"Krebs I, Glittenberg C, Ansari-Shahrezaei S, Hagen S, Steiner I, Binder S (2013) Non-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degeneration. Br J Ophthalmol 97:1443\u20131446","journal-title":"Br J Ophthalmol"},{"key":"2113_CR7","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1136\/bjophthalmol-2013-304670","volume":"98","author":"M Suzuki","year":"2014","unstructured":"Suzuki M, Nagai N, Izumi-Nagai K, Shinoda H, Koto T, Uchida A et al (2014) Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol 98:1186\u20131191","journal-title":"Br J Ophthalmol"},{"key":"2113_CR8","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.oret.2019.04.018","volume":"3","author":"GT Kokame","year":"2019","unstructured":"Kokame GT, deCarlo TE, Kaneko KN, Omizo JN, Lian R (2019) Anti-Vascular endothelial growth factor resistance in exudative macular degeneration and polypoidal choroidal vasculopathy. Ophthalmology Retina 3:744\u2013752","journal-title":"Ophthalmology Retina"},{"key":"2113_CR9","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.2147\/DDDT.S115121","volume":"10","author":"S Yang","year":"2016","unstructured":"Yang S, Zhao J, Sun X (2016) Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Dev Ther 10:1857","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"2113_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1167\/iovs.18-24387","volume":"60","author":"R Agrawal","year":"2019","unstructured":"Agrawal R, Balne PK, Wei X, Bijin VA, Lee B, Ghosh A et al (2019) Cytokine profiling in patients with exudative age-related macular degeneration and polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci 60(1):376\u2013382","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2113_CR11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000381865","volume":"234","author":"BD Kuppermann","year":"2015","unstructured":"Kuppermann BD, Goldstein M, Maturi RK, Pollack A, Singer M, Tufail A et al (2015) Dexamethasone intravitreal implant as adjunctive therapy to ranibizumab in neovascular age-related macular degeneration: a multicenter randomized controlled trial. Ophthalmologica 234:40\u201354","journal-title":"Ophthalmologica"},{"issue":"8","key":"2113_CR12","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1097\/IAE.0b013e318285cb71","volume":"33","author":"TM Ranchod","year":"2013","unstructured":"Ranchod TM, Ray SK, Daniels SA, Leong CJ, Ting TD, Verne AZ (2013) LuceDex: a prospective study comparing ranibizumab plus dexamethasone combination therapy versus ranibizumab monotherapy for neovascular age-related macular degeneration. Retina 33(8):1600\u20131604","journal-title":"Retina"},{"key":"2113_CR13","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1136\/bjophthalmol-2014-305684","volume":"99","author":"P Calvo","year":"2015","unstructured":"Calvo P, Ferreras A, Al Adel F, Wang Y, Brent MH (2015) Dexamethasone intravitreal implant as adjunct therapy for patients with wet age-related macular degeneration with incomplete response to ranibizumab. Br J Ophthalmol 99:723\u2013726","journal-title":"Br J Ophthalmol"},{"key":"2113_CR14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/IAE.0000000000001264","volume":"37","author":"S Rezar-Dreindl","year":"2017","unstructured":"Rezar-Dreindl S, Eibenberger K, Buehl W, Georgopoulos M, Weigert G, Krall C et al (2017) Role of additional dexamethasone for the management of persistent or recurrent neovascular age-related macular degeneration under ranibizumab treatment. Retina 37:962\u2013970","journal-title":"Retina"},{"key":"2113_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/2474126416683299","volume":"1","author":"B Todorich","year":"2017","unstructured":"Todorich B, Thanos A, Yonekawa Y, Mane G, Hasbrook M, Thomas BJ et al (2017) Simultaneous dexamethasone intravitreal implant and anti-vegf therapy for neovascular age-related macular degeneration resistant to anti-vegf monotherapy. J Vitreoret Dis 1:65\u201374","journal-title":"J Vitreoret Dis"},{"key":"2113_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/5612342","volume":"2018","author":"E Giancipoli","year":"2018","unstructured":"Giancipoli E, Pinna A, Boscia F, Zasa G, Sotgiu G, Dore S et al (2018) Intravitreal dexamethasone in patients with wet age-related macular degeneration resistant to anti-vegf: A prospective pilot study. J Ophthalmol 2018:1\u20138","journal-title":"J Ophthalmol"},{"key":"2113_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/j.1755-3768.2008.01502.x","volume":"88","author":"JB Jonas","year":"2010","unstructured":"Jonas JB, Libondi T, Golubkina L, Spandau UH, Schlichtenbrede F, Rensch F (2010) Combined intravitreal bevacizumab and triamcinolone in exudative age-related macular degeneration. Acta Ophthalmol 88:630\u2013634","journal-title":"Acta Ophthalmol"},{"key":"2113_CR18","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1016\/j.ophtha.2013.03.016","volume":"120","author":"K Tozer","year":"2013","unstructured":"Tozer K, Roller AB, Chong LP, Sadda S, Folk JC, Mahajan VB et al (2013) Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology 120:2029\u20132034","journal-title":"Ophthalmology"},{"key":"2113_CR19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1089\/jop.2012.0173","volume":"29","author":"D Veritti","year":"2013","unstructured":"Veritti D, Sarao V, Lanzetta P (2013) Bevacizumab and triamcinolone acetonide for choroidal neovascularization due to age-related macular degeneration unresponsive to antivascular endothelial growth factors. J Ocul Pharmacol Ther 29:437\u2013441","journal-title":"J Ocul Pharmacol Ther"},{"key":"2113_CR20","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1007\/s00018-016-2147-8","volume":"73","author":"A Kauppinen","year":"2016","unstructured":"Kauppinen A, Paterno JJ, Blasiak J, Salminen A, Kaarniranta K (2016) Inflammation and its role in age-related macular degeneration. Cell Mol Life Sci 73:1765\u20131786","journal-title":"Cell Mol Life Sci"},{"key":"2113_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.imlet.2012.05.005","volume":"147","author":"A Kauppinen","year":"2012","unstructured":"Kauppinen A, Niskanen H, Suuronen T, Kinnunen K, Salminen A, Kaarniranta K (2012) Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells\u2014implications for age-related macular degeneration (AMD). Immunol Lett 147:29\u201333","journal-title":"Immunol Lett"},{"key":"2113_CR22","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1073\/pnas.0408835103","volume":"103","author":"M Nozaki","year":"2006","unstructured":"Nozaki M, Raisler BJ, Sakurai E, Sarma JV, Barnum SR, Lambris JD et al (2006) Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci 103:2328\u20132333","journal-title":"Proc Natl Acad Sci"},{"key":"2113_CR23","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1159\/000219686","volume":"42","author":"A Machali\u0144ska","year":"2009","unstructured":"Machali\u0144ska A, Dziedziejko V, Mozolewska-Piotrowska K, Karczewicz D, Wiszniewska B, Machali\u0144ski B (2009) Elevated plasma levels of C3a complement compound in the exudative form of age-related macular degeneration. Ophthalmic Res 42:54\u201359","journal-title":"Ophthalmic Res"},{"key":"2113_CR24","first-page":"345","volume":"19","author":"A Oliver","year":"2006","unstructured":"Oliver A, Ciulla TA (2006) Corticosteroids as antiangiogenic agents. Ophthalmol Clin North Am 19:345\u2013351","journal-title":"Ophthalmol Clin North Am"},{"key":"2113_CR25","first-page":"1891","volume":"40","author":"H Oh","year":"1999","unstructured":"Oh H, Takagi H, Takagi C, Suzuma K, Otani A, Ishida K et al (1999) The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci 40:1891\u20131898","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2113_CR26","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.ophtha.2008.07.007","volume":"115","author":"S Schaal","year":"2008","unstructured":"Schaal S, Kaplan HJ, Tezel TH (2008) Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 115:2199\u20132205","journal-title":"Ophthalmology"},{"key":"2113_CR27","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/archopht.1992.01080140115038","volume":"110","author":"HW Kwak","year":"1992","unstructured":"Kwak HW, D\u2019Amico DJ (1992) Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 110:259\u2013266","journal-title":"Arch Ophthalmol"},{"key":"2113_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1167\/iovs.10-5285","volume":"52","author":"JE Chang-Lin","year":"2011","unstructured":"Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD et al (2011) Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 52:80\u201386","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2113_CR29","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1001\/jama.293.12.1509","volume":"293","author":"P van Wijngaarden","year":"2005","unstructured":"van Wijngaarden P, Coster DJ, Williams KA (2005) Inhibitors of ocular neovascularization: promises and potential problems. JAMA 293:1509\u20131513","journal-title":"JAMA"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02113-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-02113-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-02113-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T02:23:21Z","timestamp":1649384601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-02113-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,9]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["2113"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-02113-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-282965\/v1","asserted-by":"object"}]},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,9]]},"assertion":[{"value":"22 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author on request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability and materials"}},{"value":"The study protocol adhered to the tenets of the Declaration of Helsinki and was approved by the local Institutional Review Board (LEC 05\u201318-089) at L.V. Prasad Eye Institute. All study participants gave a written informed consent before enrollment. Patients were recruited from March 2017 through November 2019.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}